000 03394nam a22004575i 4500
001 978-1-61779-407-0
003 DE-He213
005 20140220083251.0
007 cr nn 008mamaa
008 111214s2012 xxu| s |||| 0|eng d
020 _a9781617794070
_9978-1-61779-407-0
024 7 _a10.1007/978-1-61779-407-0
_2doi
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
100 1 _aGajewski, Thomas F.
_eeditor.
245 1 0 _aTargeted Therapeutics in Melanoma
_h[electronic resource] /
_cedited by Thomas F. Gajewski, F. Stephen Hodi.
264 1 _aNew York, NY :
_bSpringer New York,
_c2012.
300 _aXIV, 377p. 27 illus., 22 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCurrent Clinical Oncology
505 0 _aMolecular targets and subtypes in melanoma -- Melanoma genomics -- Predictive biomarkers as a guide to future therapy selection in melanoma -- KIT as a therapeutic target for melanoma -- Targeted inhibition of B-Raf -- The notch and B-catenin pathways -- STAT3 and Src signaling in melanoma -- Targeting the mTOR, PI3K and AKT pathways in melanoma -- Targeting apoptotic pathways in melanoma -- Anti-angiogenesis therapy in melanoma -- Melanoma antigens recognized by T lymphocytes -- Melanoma vaccines -- Adoptive cell therapy for the treatment of metastatic melanoma -- Anti-CTLA-4 monolonal antibodies -- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies -- Treatment of melanoma with agonist immune co-stimulatory agents -- Novel cytokines for immunotherapy of melanoma -- Modulating the tumor microenvironment.
520 _aMelanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.
650 0 _aMedicine.
650 0 _aOncology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOncology.
650 2 4 _aCancer Research.
700 1 _aHodi, F. Stephen.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781617794063
830 0 _aCurrent Clinical Oncology
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-61779-407-0
912 _aZDB-2-SME
999 _c101604
_d101604